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Dose-Response Relationship in
Multistage Carcinogenesis: Promoters
by Kirk T. Kitchin,' Janice L. Brown,' and R. Woodrow
Setzer2
Publisheddose-responsecurvesofpromotersofmultistagecarcinogenesiswereselectedthatmetthecombinedcriteria
oflongstudytimes, multipledoses, andlow doses. Inratliver, 12dose-responsestudiesof7differentpromoters(phenobar-
bital, 2,3,7,8-tetrachlorodibenzo-p-dioxin [TCDDI, clophen A-50 (a polychlorinated biphenyl), a-, i-, and '-
hexachlorocyclohexane [HCHJ,andchloroform)wereselected.Thesepromoterswerestudiedfor7486weeksandeither
alteredhepaticfociorhepaticcancerweredetermined. Thedosesrangedfrom 1 ng(TCDD)to400mg(chloroform). In
mouseskin, 10dose-responsestudiesof4promoters(12P-0e-radecanoylphorbol-13-acetate rIPAJ, anthralin,chrysarobin,
and2,6-di-tert-butyl-4hydroperoxyl-2,5-cyclohexadienone [BHTOOHJ)wereselected. Inthese mouseskin studiesthe
dosesrangedfromOA25nmole(TPA)to20,000nmole(BHTOOH) permouse. Thelengthoftimepromoterswereapplied
totheskinvariedbetween 15and60weeks.Eitherskinpapillomasorcarcinomasweredetermined. Thedose-response
relationshipsarepresentedonthebasisofmolesofpromoter, percentageofthefullyeffectivep ingdose, orpercentage
ofthe acute oral rat LDso. The degree ofconcavity ofthe dose-response curves was determined. Theavailable dose-
responsedataarecritiquedanddiscussedonthebasisoffuture researchneedsforbolk ically basedcancerriskasement
models.
Introduction
As welearn moreaboutmultistagecarcinogenesis, moredata
accumulate onthe numberofstages andthedose-response rela-
tionshipofeach individual stage. Afterelucidation ofthe initia-
tion stepofcarcinogenesis, promotionofcarcinogenesis wasthe
second stageofmultistepcarcinogenesis identified. Fordecades
it has been stated that initiators ofcarcinogenesis are probably
linear in their dose-response relationship (extrapolated below
theexperimental range), while promoters ofcarcinogenesis are
nonlinear and exhibit thresholds ofbiological response.
With the developmentofa mathematical two-stage model of
carcinogenesis by Moolgavkar and his co-workers (1), the im-
portance of the dose-response relationships of each of the
individual stepsofmultistagecarcinogenesishasbecome more
obvious. Eachimportantbiological processinMoolgavkar's two-
stage model (first mutation, second mutation, birth and death
rates for initiated cells) is time and dose dependent. To use
biologically based models ofcancer risk assessment, we must
first experimentally determine the dose-response relationship
for promoters.
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Inthis study wehavecompiledpublisheddose-responserela-
tionships forpromotersofcarcinogenesisthatmeetthemultiple
criteriaofa)long study times (7-86weeks), b)multipledoses,
andc)lowdosesselected. Withoutalongstudytime, adifference
oflatency might be mistaken for a difference in potency ofthe
promoter. The resulting dose-response curves from 22 ex-
perimentalstudiesof11 differentchemicalsareexaminedonthe
basis ofpicomole/kilogram, nmole/mouse, percentage ofthe
maximally promoting dose, and percentage oftheacute LD5o.
Thedose-response curves wereexaminedforconcavity (slope
increases with dose in the low-dose range), experimental
thresholds, slopes, andplateausofbiologicaleffects. Thisdose-
responsestudyofpromotersofcarcinogenesishasutilityforboth
riskassessmentandtheregulation ofenvironmental chemicals.
Rat LiverStudies
Table 1 presentsthepromoters, doserange, lengthofpromo-
tion, initiator, number and type of experimental animals,
biologicalendpoint, andreferenceforthe 12selectedexperimen-
tal studiesofpromotionofcarcinogenesis in ratliver. Although
noanimal species ortargetorgans weredeliberately excluded,
theonlystudiesfoundthatsimultaneously metthecriteriaoflong
studytimes, multipledose, andlowdoseswereconductedinrat
liver and mouse skin. After initiation by either diethylnitro-
samine (DEN), dimethylnitrosamine (DMN), or N-nitro-
somorpholine(NNM), ratswereadministeredvariouspromoters
anywherebetween7and86weeks, depending ontheindividual
experimental study (Table 1). In only two studies, both withKITCHINETAL.
Tble 1. Experimental design of12 dose-response studies of7different rat-liver tumor promoters. a
Promoter
Chemical Dose range, mg/kg Exposure time, weeks Initiator Rat strain/sex (n) Biological end point Reference
Phenobarbital 4.7-75 70 DEN S-D/M (19-23) Carcinoma (2)
Phenobarbital 3.84-96. 86 DMN+DIET Porton/M (8-9) Carcinoma (3)
Phenobarbital 0.75-75 18 NNM Lewis/F (6) Foci (4)
Phenobarbital 0.78-39 26 DEN F344/F (NA) Foci (5)
TCDD 0.1-100 mg 26 DEN F344/F (NA) Foci (5)
Clophen A 50 0.1-10 12 DEN S-D/F (4) Foci (6)
Clophen A 50 2-100 7 DEN S-D/F (4) Foci (7)
Clophen A 50 0.1-50 11 DEN S-D/F (NA) Foci (8)
a-HCH 0.1-20 20 NNM Wistar/F (4) Foci (9)
,3-HCH 0.03-10 20 NNM Wistar/F (4) Foci (9)
y-HCH 0.1-30 20 NNM Wistar/F (4) Foci (9)
Chloroform 25-400 11 DEN S-D/F (4-6) Foci (6,10)
Abbreviations: GGT, y-glutamyltranspeptidase; HCH, hexachlorocyclohexane; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; DEN, diethylnitrosamine; NNM,
N-nitrosomorpholine; DMN, dimethylnitrosamine; S-D, Sprague-Dawley; NA, not available.
aAll foci studies usedGGTasamarkerwiththeexceptionofoneclophenA50study (8), whichusedATPase. ThePitotetal. (5) studiesofphenobarbital andTCDD
employed threepreneoplastic markers, GGT, ATPase, andglucose6-phosphatase. Themolecular weights ofthesecompounds arephenobarbital (255.25), TCDD
(321.96), clophen A 50 (355.7), chloroform (119.37), and ca-, ,-, ,and oy-HCH (290.8).
phenobarbital (2,3), didtheexperimentprogresstohepaticcar-
cinoma. In the 10 remaining studies, preneoplastic foci were
determined. For rat liver, the promoting chemicals were
phenobarbital, chloroform, a-, ,-, and y-hexachlorocyclohexane
(HCH), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and
Clophen A 50 (a polychlorinated biphenyl). Thedoses ranged
from a low of 0.0000001 mg/kg for TCDD to 400 mg/kg for
chloroform, about 10 orders ofmagnitude.
Phenobarbital wasgiventomale Sprague-Dawley ratsindoses
of62.5, 125, 250, 500, and 1000ppmindrinking waterbyPereira
etal. (2). Rats (19-23 per treatment group) were initiated with
80mg/kg DENby gavage. After70weeksofphenobarbital pro-
motion, sections ofrat liver were examined and classified into
fourdifferenttypesofcarcinomas: trabecular(themostcommon
finding), adenocarcinoma, mixed carcinoma, and poorly dif-
ferentiatedcarcinoma. Phenobarbital promotionat250, 500, and
1000ppmsignificantly increasedtheincidenceofcarcinoma, but
thephenobarbital treatment groups at62.5 and 125ppmdidnot
(Fig. 1).
The second study thatproceeded all theway to full livercar-
cinoma was performed by Driver andMcLean (3). Male SPF-
Portonrats(Wistarderived)wereinitiatedby 15mg/kgofDMN.
Theanimalswereswitchedfromaprotein-freediettoadietcom-
posedof50% caseintoincreasemitosisjustbeforetheinitiation
step. Therats(10perexperimentalgroup) werethenexposedto
40, 100, or 1000ppmphenobarbital intheirdrinkingwaterfor86
weeks. Hepatocellularcarcinomawasdiagnosedbylossofnor-
mal liverarchitecture, thickened, irregularlivercellplates, and
highly abnormal cellularmorphology. Onlytheanimal receiv-
ing 1000 ppm phenobarbital showed a statistically elevated
incidenceoflivercarcinomacomparedtotheDEN-alone treat-
ment group (Fig. 1). The two lower doses of40 and 100 ppm
phenobarbitalwerebelowtheexperimentalthresholdofresponse
(Fig. 1) (3).
A thirddose-response study withphenobarbital wasreported
by Kunz et al. (4). After initiation with 120 ppm of NNM in
drinkingwaterfor7days,sixfemaleLewisratsweregivendoses
of0.75, 7.5, or75mg/kgofphenobarbitalfor 18weeks. Theliver
foci were scoredfor-y-glutamyltranspeptidase (GGI). Onlythe
75 mg/kg phenobarbital group showed an elevation in GGT-
positive foci (4).
Pitotetal. (5)performedastudywithphenobarbital (at0.001,
0.005,0.01, and0.05% infood; (Fig. 2)andTCDD(0.1, 1, 10, and
100ng/kg/day, (Fig. 3)aspromoters. Fischer344ratsweresub-
jected to a 70% partial hepatectomy before an oral dose of 10
mg/kg DEN wasgiven. After26 weeks ofpromotion, rat liver
sections were stained for GGT, ATPase, and glucose
6-phosphatase. Alteredhepatic foci werescoredusingall three
markers. Rats promoted by the highest phenobarbital dose
(0.05%) were statistically elevated in the number of altered
hepatic foci, whereas rats exposed to the lowest dose of
phenobarbital (0.001%) actually had a statistically decreased
numberofalteredhepaticfoci. Thisisexperimentalevidencefor
an antipromotional effect ofa known promoter ofhepatocar-
cinogenesis. TCDD showed the samedose-response relation-
ship, asdidphenobarbital (5). Atthetwolowestdosesof0.0001
and0.001lgckgofTCDD,thenumberofalteredhepaticfoci was
significantly reduced. Only atthe higherdose of0.1 p/kg did
TCDD effectively promote carcinogenesis in this two-step ex-
perimental system.
Thepolychlorinatedbiphenyl mixtureClophenA50hasbeen
examinedbyaGermangroupinaseriesofthreesimilarstudies
(6-8). FemaleSprague-Dawley rats(4-6femaleratspertreat-
mentgroup)wereinitiatedwith8mg/kgofDEN. Thepromoting
chemicalClophenA50wasgiveneitherthreetimes aweekfor
11 weeks(6), onceaweekfor7weeks(7), orthreetimesaweek
for 11 weeks(8). Inthesethreestudiesthedailydoserangedfrom
0.1 to 100mg/kg. IntwoofthestudiesGGITfociwerescored(6,7)
andinoneATPasewasusedasamarker(8). Fivetoonehundred
mg/kg ofClophen A 50significantly increased the number of
alteredhepatic foci, butdosesbelow 5 mg/kgdid not(Fig. 4).
Thea-, ,-and y-HCHisomers wereusedinadose-response
studyofpromotioninfemaleWistarrats(9) (Fig. 5). Thedoses
selectedwere0.1, 0.5, 2, 7, and20mg/kgfora-HCH;0.03,0.2,
1,3, and 10mg/kgfor,B-HCH; and0.1,0.5, 2.5, 10, and30mg/kg
for'y-HCH, theinsecticidalisomer. Ratswereinitiatedwith250
mg/kgofNNMbygavageandpromotionwiththethreeisomers
ofHCH started 8 weeksafterinitiation. Afterthepromotional
periodof20weeks, ratliver sections wereexamined forGGT-
positive foci. With a-HCH, significant increases in GGT
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FIGURE 1. Dose-response relationship between percent incidence of hepatic
cancer inmale ratliverandthe logofthedoseofphenobarbitalexpressedas
picomole per kilogram (2,3).
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FIGURE 2. Dose-response relationshipbetweennumberoffemaleratliverfoci
andthelogofthedoseofphenobarbitalexpressedaspicomoleperkilogram(5).
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FIGURE 3. Dose-response relationship between number offemale rat liver foci
and the log ofthedose of2,3,7,8-tetrachlorodibenzo-p-dioxin expressed as
femtomole per kilogram.
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FIGURE 5. Dose-response between number offemale rat liver foci (mean with
SD errorbars)andthe log ofthedoseofct-hexachlorocyclohexane (HCH),
0-HCH, -rHCH expressed as picomole perkilogram (9).
FIGURE 4. Dose-response relationship betweennumberoffemale rat liver foci
andthelogofthedoseofClophenA50, apolychlorinatedbiphenyl mixture,
expressed as picomole perkilogram.
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FIGURE 6. Dose-response relationship betweennumberofweanling female rat
liverfoci (expressed aspercentageofcontrol values)andthelogofthedose
ofchloroform expressed as picomole perkilogram (6).
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AIble2. Experimental design of10dose-response studies of4different femalemouse skin tumor promoters.
Promoter
Chemical Dose range, nmole/mouse Exposure time, weeks Initiator Mice Biological end point Reference
TPA 0-20 34 DMBA CD-I %P, P/M (12)
TPA 1-20 52 DMBA CD-I %C (12)
TPA 0.425-6.8 15 DMBA SENCAR %P, P/M (13)
TPA 6.8 45 DMBA SENCAR %C (13)
TPA 0.85-6.8 30 MNNG SENCAR %P, P/M (14)
TPA 1.7-10. 30 MNNG CD-i %P, P/M (14)
Anthralin 50-880 27 DMBA SENCAR %P, P/M (13)
Chrysarobin 50-220 30 DMBA SENCAR %P, P/M, %C (13)
Chrysarobin 25-440 30 MNNG SENCAR %P, P/M (14)
Chrysarobin 25-440 30 MNNG CD-i %P, P/M (14)
Chrysarobin 25-440 60 DMBA SENCAR P/M, %C, C/M (11)
BHTOOH 0-20,000 30 DMBA SENCAR %P, P/M, %C (15)
Abbreviations: TPA, 12-O-tetradecanoylphorbol-13-acetate; BHTOOH, 2,6di-tert-butyl-4-hydroperoxyl-2,5-cyclohexadienone; DMBA, 7,12-dimethylbenz[alan-
thracene; MNNG, N-methyl-N'-nitro-N-nitrosoguanidine; %P, percentofmicewithpapillomas; P/M, papillomaspermouse; %C, percentofmice with skincar-
cinomas; C/M, carcinomas permouse.
aThe molecular weightsofthese compoundsareTPA (616.9), anthralin (226.24), chrysarobin (240.27), andBHTOOH (252.4). All studies used30 mice perex-
perimental group except fortheBHTOOH study, which used 25 mice per group.
fociwereobservedat2mg/kgandabove(Fig. 5). Forj3-HCHthe
highestdosesof3 and 10mg/kg increasedfocinumber(Fig. 5).
Lowerdosesof,B-HCHwerenotstatisticallysignificant, chief-
ly because of high variation among animals. y-HCH showed
significantpromotional activity atdoses of0.1, 2.5, 10, and 30
mg/kg (Fig. 5), whereas thedoseof0.5 mg/kg-y-HCHdidnot.
Thedose-response relationship forchloroform was studiedby
Deml and Oesterle (6,10). After initiation ofSprague-Dawley
ratsby 8mg/kg DEN, variousdosesofchloroform(25, 100, 200,
and 400 mg/kg) were administered twice a week for 11 weeks.
Promotion wasquantitatedbyGGT-positive ratliverfoci. Inthis
study, dosesof100, 200, and400mg/kgofchloroformincreased
thenumberoffoci, but25 mg/kgofchloroform lackedpromo-
tional activity (Fig. 6).
MouseSkin Studies
Anoutlineof10experimental studiesoffourdifferentmouse
skin promoters (12-O-tetradecanoylphorbol-13- acetate [TPA],
chrysarobin, anthralin and 2,6-di-tert-butyl-4-hydroperoxyl-
2,5-cyclohexadienone [BH1XOOH])performedineitherfemale
CD-1 orSENCARmiceispresentedinTable2. Eachindividual,
study mayexpressdataaseitherpercentpapillomas, papillomas
permouse, percentcarcinomasorcarcinomas permouse. Nor-
mallyonly2endpoints, mostcommonlypercentpapillomasand
papillomas/mouse, areavailable persingleexperiment. In one
case(11)threedifferentbiological endpoints areavailable atthe
same experimental time. Although one study was for only 15
weeks, theothers rangedbetween27and60weeks ofskinpro-
motion. Thedosesemployedrangedoveraboutfivelogcycles,
from 0.425 nmole/mouse for TPA to 20,000 nmole/mouse for
BHTOOH. Only 2 (12,15)ofthe 10experimental studies includ-
ed aconcurrentcontrol groupgiven zerodoseofthepromoter.
Verma and Boutwell used TPA as a mouse skin promoter
followinginitiationofCD-1 mice(30pertreatmentgroup)with
200nmole/mouseofDMBA(12). Thisstudy includeddosesof
TPAof0,0.01,0.1, 1,2, 5, 10, and20molepermouseandisthe
most extensive dose-response study presented in Table 2.
Papillomas weredeterminedafter34weeksofpromotion (Fig.
7): carcinomas werequantitatedat52weeks(Fig. 8). Papillomas
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FIGURE 7. Dose-response relationship between numberofpapillomas/mouse
and the log of the dose ofeither 12-O-tetradecanoyphorbol-13-acetate or
chrysarobin expressed as picomole per CD-1 mouse (12,14).
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FiuRE 8. Dose-response relationshipbetween percent skin carcinoma in CD-I
or SENCAR mice and the log of the dose of either 12-O-tetradecanoyl-
phorbol-13-acetate, crysarobin, or 2,6-di-tert-butyl-4-hydroperoxyl-2,5-
cyclohexadienone expressed as picomole per mouse (11,12,15).
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SENCAR MICE response relationship for chrysarobin-induced papillomas in
CD-1 mice is shown in Figure 7.
Inarelated60-weekstudy, Kruszewskietal. (11)used25, 100,
220, and 440 nmole ofchrysarobin in SENCAR mice (30 per
treatment group) previously initiated with 25 nmole/mouse of
DBMA. Thisstudydeterminedpercentpapillomas, papillomas
permouse, andpercentskincarcinomasatasingle60-weektime
point (Fig. 8) (11).
The hydroperoxide metabolite ofbutylated hydroxytoluene
AJA-A was used by Taffe and Kensler (15) in a 30-week promotional
dose-response studyinSENCARmice(25pertreatmentgroup)
initiated withDMBA(20nmole/mouse;Fig.9). Thus, thedoses
WIN / chosenwere0, 2000, 8000, and20,000nmoleofBH1OOH and
arethehighestmolardosesofallthe 10selectedstudiesofmouse
I + *1 skinpromoters. Thehigherdoses, 8000and20,000nmole, pro-
5 6 7 8 moted mouse skin carcinomas, but2000 nmole BHTOOH did
not (Fig. 8).
FIGURE 9. Dose-response relationship between number papillomas/mouse and
the log ofthedose ofeitherTPA, anthralin, chrysarobin, orBHTOOH ex-
pressed as picomole per mouse (11,13,15).
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Comparison ofRat LiverPreneoplastic Foci
on a Femtomole perKilogramBasis
Figure 10showsthedose-responserelationshipforsevendif-
ferentratliverpromoters. Thecommon Y-axis isthepercentage
ofcontrol focinumber. TheX-axisislogarithmically calibrated
and ranges over 10 log cycles ofpromoter dose from a low of
about 102(TCDD) to ahighof1012(chloroform)fmole/kgbody
weight. Most ofthe seven dose-response curves are clustered
fairly closetogether, withTCDD(16)andchloroformbeingthe
exceptions atverylowandhighdoses,respectively. On amolar
0 i basis,TCDDisabout 100,000timesmorepotentthantheother
1/4 ) * ratliverpromoters showninFigure 10. Incontrast, chloroform
/+; / / is about 1/100 as potent on a molar basis as the majority ofrat
-Msol,>* / / liver promoters. This remarkabledifferenceinmolarpotencies
A, 5? -*ofchemicalsthatpromoteratlivercarcinogenesis maybedueto
o-0c? * threedistinctmechanismsatlow, medium, andhighmolardose
I__I 1 ranges. Thethreerespectivemechanismscouldbehigh-affinity
receptormediated(forTXDD), mitogenesisorcellproliferation
mediated (forthe fivechemicals ofintermediatepotency), and
rofratliverfociandthe cell death and regenerative cell proliferation mediated (for
arcincgenesisexpressed chloroform).
as remiomomeperK110gIrlMkJ,O,Y).
were not found after exposure to 0.01 or 0.1 nmole ofTPA per
mouse. All fivehigherdoses (1-20nmole/mouse) ofTPA pro-
moted skin papillomas (Fig. 7) and carcinomas (Fig. 8).
DiGiovanni etal. (13) studiedpapillomadevelopmentinSEN-
CAR mice (30 per treatment group) initiated with 10 nmole/
mouse DMBA and subsequently promoted for 15 weeks with
0.425, 0.85, 1.7, 3.4, and68nmoleofTPA(Fig. 9). Thepercen-
tageofmicewithcarcinomas wasdeterminedafter45weeksof
promotion with 6.8 nmole of TPA. Dose-response studies of
papillomas werealsodonewith50, 100, 220, and880nmoleof
anthralin (13) (Fig. 9) and with 50, 100, or 220 nmole of
chrysarobin (11) (Fig. 9). In a subsequent 30 week dose-
responsestudy, DiGiovannietal. (14)measuredpapillomafor-
mation caused by either TPA (0.85-10 nmole) or chrysarobin
(25-440nmole) inCD-i andSENCARmice(30pertreatment
group)initiatedwith2500nmole/mouseofMNNG. Thedose-
Comparisons on aPicomole perMouseBasis
Figure8displaysthreedose-responsecurves forthepercent
carcinomas in mice exposed to different doses ofeither TPA,
chrysarobin, or BHTOOH. Both TPAandchrysarobin show a
plateau inthepercentcarcinomas, whereastheBH1O0Hstudy
did nothaveenough different doses todemonstrate this trend.
The three compounds vary in molar potency by more than
1000-fold. Thedose-responsecurvesarefairly steepforallthree
compounds,buttheTPAandchrysarobinexperiments werenot
carrieddowntopromoterdosesthatresultedin0% carcinoma.
Neitherofthesetwo studies includedacontrol group inwhich
mice were initiated and then given zero dose ofthe promoter
understudy. Incontrast, theBHTOOHstudycontainedbothan
initiatedcontrolgroupgivenzerodoseofthepromoter(which
had 0% carcinomas) and also a 2000pmole ofBHTOOH per
mouse experimental group, which also developed 0% car-
cinomas. In promoting mouse skin carcinomas, BHTOOH
demonstrated anexperimental threshold (Fig. 8).
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InCD-1 mice, TPAandchrysarobingavedose-relatedcurves
forpapillomas/mouse (Fig. 7). Very fewpapillomaswerecaused
bychrysarobin intheCD-1 mouse, andthreeexperimentaldoses
showed no effect whatsoever. Although doses of 10 and 100
pmole ofTPA did not induce skin papillomas, higher doses of
TPA showedadose-responsecurvewithahighslope. Onlythe
TPA study included a concurrent control group exposed to the
initiator and zero dose ofthe promoter.
In the moresensitive SENCARmouse, dose-responsecurves
for papillomas/mouse are available for TPA, anthralin, chry-
sarobin, andBHTOOH (Fig. 9). The strongpromoterTPAagain
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FIGURE 11. Dose-response relationship between numberofratliver foci and the
percentage ofthe oral ratLD50(24). The X-axis is logarithmically calibrated
in units of 100, 10, 1, 0.1, 0.01, and 0.001% oftheLD., ofeach individual
chemical (5,6,9).
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FIGURE 12. Dose-response relationshipbetween numberofratliverfoci andthe
percentageofmaximallypromoting doseofeach individualpromoter. The
X-axis islogarithmically calibrated inunitsofthe 100, 10, 1,0.1,0.01, 0.001%
ofthe maximally promoting dose ofeachindividual chemical (5,6,9).
showed a high slope, witha plateau atabout 14 papillomas per
mouse. Anthralinandchrysarobin showalowerslope, with in-
dicationsofaplateau ataboutfourtosixpapillomaspermouse,
a level substantially below that achieved by TPA (Fig. 9).
BHTOOH was tested in only three doses, and thusthe slope of
the dose-response curve is not really clear.
Comparison on a PercentLD_.Basis
Thepromotional potency normalizedby the lethality potency
ofachemical shows ifachemicalpossessesunusualpromotional
power without accompanying toxicities. Therefore, Figure 11
showsthenumberofhepatic focigraphedonthebasisofpercent
of the chemicals' LD50/kilogram rather than femtomole/
kilogram. UsingthisapproachTCDDisnotaremarkablypotent
hepatic promoter. Normalized on the basis of acute lethality,
3-HCH isthemostpotentchemicalandchloroform, again, isthe
least potent. Of the seven promoters, TCDD increased the
hepaticfocinumbertothesmallestextent, lessthan300% ofcon-
trolvalues. DuetolackofLD50information, thefourskintumor
promoters cannot be compared on apercentLD5obasis.
Comparison on a Percentage of
Maximally Promoting Dose Basis
To determine ifthe shape ofthe promotional dose-response
curve is fairly similar between chemicals, the maximally pro-
moting doseofeachchemical was usedanormalization factor.
Figure 12 displays the dose-response curves for hepatic foci
number of seven promoters. For each promoter, the dose that
producedthemaximal promotion is setat 100% on the X-axis.
ThenthelogarithmicX-axis iscalibratedas 100, 10, 1,0.1, 0.01,
and0.001% ofthemaximallypromotingdoseofeachindividual
chemical. TheY-axis isfocinumberexpressedaspercentageof
concurrentcontrols. Withtheexceptionofthethree isomers of
HCH, allthecurvesaregenerallythe same. At 10% ofthemax-
imallypromotingdose, fourchemicalshavefallentonearlythe
no-effectlevel. However, at 10% ofmaximallypromotingdose
all three HCH isomers show about 300% of the control foci
number. Evenatadoserangeofapproximately 1 to 10% ofthe
maximally promoting dose, all three isomers ofHCH show a
numerically higher number offoci, although these elevations
were not always statistically significant. The two lowest doses
that did give statistically significant increases in hepatic foci
numberwere -y-HCH at0.1 mg/kg and a-HCH at0.5 mg/kg.
Antipromotional DoseRangeof
ICDDandPhenobarbital
Thephenobarbital andTCDD studies ofPitot etal. (5) have
shown an apparent "protective" or "antipromotional " dose
range. For phenobarbital, low doses are protective in both
Sprague-Dawley andFischer344rats(5). At0.001% phenobar-
bitalinthediet, aprotectiveeffectisseeninFischer344ratswith
respect to both number of hepatic foci and the foci volume
percentages when compared with rats receiving nophenobar-
bital. Thephenobarbitalexperimentswerenotcarriedouttoas
lowlevelsastheTCDDexperiments(Figs. 10-12). WithTCDD
as the hepatic promoting agent, the protective dose range
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included two experimental doses of 0.0001 and 0.001
.tg/kg/day. This study did not demonstrate an experimental
threshold fortheprotectiveeffectofphenobarbital andTCDD.
Very low dose studiesofthethreeisomersofHCHinWistar
rats found noprotectivedosesofHCH(Fig. 9)(9). Atthelowest
dosesof,3-HCHand-y-HCH, theexperimental studies showed
increases, though not always statistically significant, ofabout
double the control numbers ofhepatic foci. Thus, in the dose
range below 10% of the maximally promoting dose, two
chemicals (TCDD and phenobarbital) show protective effects
(5), but three chemicals (a-, f3- and7y-HCH) do not (9).
With respect toother ratlivereffectsofTCDD, inductionof
arylhydrocarbonhydroxylase activitydoes notshowprotective
effects at low doses (17). This study used 10 different doses
down to0.0006Ag/kg, alevel corresponding toonly 0.0027 %
ofthe LD50 (17).
Dose-response relationships in multistage carcinogenesis
have been both experimentally studied and much debated
(18-21). However, in the low-dose region, the amount ofex-
perimental information available on chemically induced car-
cinogenesis is quite limited. Experimental approaches to the
issue ofdose-response relationships are limited by statistical
considerations. To determine with 95% probability an animal
carcinogenthatcauses5, 2,0.1, and 0.001 % cancerrequires59,
149, 2995, and29,950experimentalanimals, respectively (22).
Thislargenumberofexperimental animalsisrequired forequal
sample sizes(treated andcontrol) with no tumorsinthecontrol
group. Thelargestexperimental group ever run was2109mice
in the National Center for Toxicological Research 2-acetyl-
aminofluorene study (23).
Experimental Thresholds
Inthis papertheterm "experimentalthreshold" isdefined as
thedose atwhichno-observable 1-1 effect(NOEL)isobtained
in a particular experiment. By definition, an experimental
threshold should exist for every chemical in any given ex-
perimental system. The major determinants of an experimental
threshold arethesamplesize, thestandarddeviationofthestudy
parameter, and the sensitivity ofthe biological study parameter.
However,justbecause anexperimental thresholdshouldexist
doesnot meanthat anyparticularexperimentalstudyhaslocated
the experimental threshold in the dose-response curve. The
demonstrationofanexperimental thresholddoes not prove or
imply the existence of a more absolute (or nonexperimental)
threshold for achemically inducedhealtheffect. Thequestion
ofwhetherthere areabsolutethresholdsofbiological response
cannot be answered with conventional dose-response ex-
periments. Experimentalthresholds arepresentedinthis paper
becausea) they havebeenof some use in risk assessment pro-
cedures, b)they are a waytodescribethedose-response curve
intheimportantlowdoseregion, andc) theyshowthatthelimit
ofsensitivityofdetectingabiological responseforaparticular
experimental study has been reached.
With canceras theendpoint,thereisgoodevidencewithboth
phenobarbital inmale ratliver(2,3) (Fig. 1) andBHTOOH in
mouse skin (15) (Fig. 10) that experimental thresholds exist.
Dataofless strengththatsupportthisinterpretationincludeTPA
and chrysarobin mouse skin carcinoma data (11,12) (Fig. 8);
however, nocontrol group given zerodoseofthepromoter was
included in these studies. Although the slope of the dose-
Table3. Concavityandexperimental thresholdsofpromotiondose-response relationships inratliver.
Coefficient ofquadratic Statistical significance
Chemical Biological end point Reference Experimental threshold? doseterm/SE oftest forconcavity
Phenobarbitol Tumors (2) Yes 0.89 0.19
Phenobarbitol Foci/cm2 (4) Yes 0.91 0.27
Phenobarbitol Foci/cm2 (5) Yes 135.2 0.002*
Phenobarbitol Foci % volume (5) Yes 0.086 0.47
Chloroform Foci % control (6) Yes -86.0 0.996
,3-HCH Foci/cm2 (9) No8 -3.2 0.90
B-HCH Foci % volume (9) No' -0.072 0.52
y-HCH Foci/cm2 (9) No' -0.38 0.62
y-HCH Foci % volume (9) No' -0.007 0.50
a-HCH Foci/cm2 (9) No' -4.11 0.92
a-HCH Foci % volume (9) No' 0.064 0.48
TCDD Foci/cm2 (5) Yes 916.2 0.0003*
TCDD Foci % volume (5) Yes 0.011 0.50
Chlophen A50 Foci % control (6) Yes 30.2b 0.01*
Chlophen A50 Foci/cm2 (7) Yes 2.04c 0.15
Chlophen A50 (6.05) (0.013)*
Chlophen A50 Foci % volume (7) Yes 0.015 0.50
Chlophen A50 Foci/cm2 (8) Yes 1.63 0.18
Abbreviations: HCH, hexachlorocyclohexane; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.
aBy statistical tests, lowdosesofHCH isomers werenotsignificantly differentfromcontrols. However, thelow-doseHCHtreatmentgroupshadhighernumeric
values thancontrols, exhibitedhigh variance, andhadonly fourratspertreatmentgroup. Forthese reasons, itwasconsideredthatexperimentalthresholdshadnot
been fully demonstrated forthe three HCH isomers.
bThe residual SE seriously underestimated thevariance inthis model. The SEoftheregression coefficient wasestimatedusing thepooled mean SE.
cNot significant inthe4dfmodel, butsignificant intheSdfmodel, withessentially the same parameterestimates.
*p<0.05.
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Able 4. Concavity andexperimental thresholds inpromotiondose-responserelationships inmouse skin.
Coefficient of Statistical
Experimental quadratic dose significance oftest
Chemical Strain Biological endpoint References thresholds term/SE forconcavity
TPA CD-I % Pap (12) Yes 65.9 0.0048*
TPA CD-I Pap/M Yes 100.6 0.0032*
TPA CD-I % Car No -2.1 0.86
TPA CD-I % Pap (14) Yes 2.14 0.14
TPA CD-I Pap/M Yes 0.88 0.27
TPA Sencar % Pap (13) No -1.2 0.78
TPA Sencar Pap/M No 2.2 0.14
TPA Sencar % Pap (14) No -5.3 0.94
TPA Sencar Pap/M No -7.6 0.96
Anthralin Sencar % Pap (13) Yes 1.1 0.23
Anthralin Sencar Pap/M Yes -0.4 0.63
Chrysarobin CD-I % Pap (14) Yes 4.2a(2 df) 0.03*
Chrysarobin CD-I Pap/M Yes 7.02 (2 df) 0.01*
Chrysarobin Sencar % Pap (13) No 0.99 0.25
Chrysarobin Sencar Pap/M No -0.47 0.64
Chrysarobin Sencar % Pap (14) No -4.3 0.93
Chrysarobin Sencar Pap/M No -1.1 0.76
Chrysarobin Sencar % Pap (11) No 3.13 0.098
Chrysarobin Sencar Pap/M No 23.4 0.014*
Chrysarobin Sencar % Car No 11.0 0.029*
Chrysarobin Sencar Car/M No 8.9 0.036*
BHTOOH Sencar % Pap (15) Yesb 0.26 0.42
BHTOOH Sencar Pap/M Yesb 18.6 0.017*
BHTOOH Sencar % Car Yes 0.18 0.44
Abbreviations: TPA, 12-O-tetradecanoylphorbol-13-acetate; BHTOOH, 2,6-di-tert-butyl-4-hydroperoxyl-2,5-cyclohexadienone; % pap, percentofmicewith
papillomas; pap/M, papillomas per mouse; % car, percentofmice with carcinoma; car/M, carcinomas per mouse.
aAs the response atall threeofthe lowest doses was zero, thedose response wasevaluated forconcavity overthe lowest fourdoses.
bAlthoughthepercentpapillomas andpapillomas permouse were numerically higherinthelow-doseBHTOOH-treated groupsthan incontrols, this was not a
statistically significant difference.
*p<0.05.
response curve was steep, for both TPA and chrysarobin, the
lowest tested doses still had apromotional effect.
Withliverfociastheendpoint, strongevidenceforexperimen-
tal thresholds exists forphenobarbital (5), TCDD(5), Clophen
A50(6-8), andchloroform(6,10) (Fig. 10). Therewasnocon-
vincing experimental data for thresholds for altered liver foci
demonstrated for and a-, (l-, and 'y-HCH (9) (Fig. 10).
Forskinpapillomas infemaleSENCARmice, strongevidence
forathreshold exists forBHTOOH (15)andanthralin(13)(Fig.
9). TheTPA(13) andchrysarobin (11)dataareofless strength.
In female CD-1 mice, strong evidence for a threshold in skin
papillomasexistsforbothTPA(12) (twoexperimentaldoseswith
nopapillomas) andchrysarobin (14) (threeexperimental doses
with nopapillomas) (Fig. 7). As shown inTables 3and4, there
were 22 cases in which it was considered thatpromotional ex-
perimental thresholds have been demonstrated and 19 cases in
which they have not.
Thus, overall there is a sufficient amount and quality ofex-
perimental data that argue for an experimental threshold inthe
dose-response relationship of promoters of multistage car-
cinogenesis. However, only two mouse skin studies included a
controlgroupgivenzerodoseofthepromoter, andthisomission
limits the utility of the data in biologically based cancer risk
assessmentmodels. Unfortunately, only 5of22experimentspro-
ceeded all the way to the cancer. These five studies are of
phenobarbital (2,3), BHTOOH (15), TPA (12,13), and chry-
sarobin (13). Usually theavailable dose-responsedata onpro-
moters ofcarcinogenesis are limited toaltered hepatic foci and
skinpapillomas. Overallthebestdose-responsecurvesavailable
forbiologically basedcancer riskassessmentmodeling arethe
two rat-livercarcinoma studies withphenobarbital (Fig, 11).
Concave Dose-Response Curves
A concave curve lies below a straight line connecting ex-
perimentalpointsandthecontrolvaluesandhasaslopethatin-
creases with dose for low doses. To test the concavity of the
dose-response curves, datafromstudiesoftheseelevendifferent
chemicals were fit into aquadratic equation containing both a
linear and a quadratic dose term. If the coefficient of the
quadratic doseterm is foundtobepositive, this isevidence for
aconcavedose-response curve.
As itistypical fordose-response curvestoleveloffathigher
doses, only the lowest possible sets ofdoses were used. The
lowestp + 1 doses were selected, wherep is the number of
parametersinthemodel(threeforamodelwithaninterceptand
two for a model without an intercept). In two CD-1 mouse
papillomadatasets(14), alldoseschosenbythis selection rule
had zero papillomas. These twopapilloma data sets were ana-
lyzedby incorporating the nexthigherdose.
Linearregression, weightedby thereciprocal ofthe squares
oftheestimatedstandarderrorsofthemeansateachdose, when
they wereavailable, wasusedtofitquadraticdose-responses to
the endpoints, foci/cm2, foci asafractionoftotallivervolume,
fociasapercentageofcontrol levels(minus 100%), andall the
papillomadata. Modelsforthepapillomadataandfociexpressed
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as a fractionofcontrol levels were forced throughtheoriginby
not including an intercept term. A positive coefficient of the
quadratic dose term was deemed statistically significant ifthe
coefficientdividedby itsstandarderrorwasgreaterthantheap-
propriate t-value for a one-tailed, one (or occasionally, two)
degree-of-freedom test. Inonecase, theresidual standarddevia-
tion was substantially smallerthanthepooled standarderror. In
thatonecasethetestwasbasedonanestimateofthestandarder-
rorofthequadratic coefficientthatusedthepooledstandarder-
ror. Modelsfortumorprevalencewerefitusingquasi-likelihood
methodstofitgeneralized linearmodelstotheprevalencedata.
The standard deviation of residuals from the weighted least-
square models wascompared withthepooledstandarderrorof
the mean when it was available to ensure that model fit was
adequate.
The resultsofconcavityanalysisofdose-responsecurvesare
expressed in Tables 3 (rat liver) and 4 (mouse skin). Linear
regression analysis showed evidence for a concave curve for
some of the dose-response curves of a-HCH (Table 3).
Statistically significant concavity was found for some of the
dose-response curvesofphenobarbital, TCDD, ClophenA50,
TPA, chrysarobin, and BHTOOH (Tables 3 and 4). Concave
dose-responsecurves were notfoundforchloroform, 3-HCH,
y-HCH, oranthralin (Tables 3 and 4). There was somedegree
ofevidence forconcavityofdose-response curvesforall eight
biological end points of promotion in Tables 3 and 4. As the
Driverand McLean (3) phenobarbital rattumorstudy couldnot
be mathematically modeled, four experimental studies
[phenobarbital (2), TPA(12), chrysarobin (11), andBHTOOH
(15)] that proceeded all the way to tumors can be examined for
concavity ofdose-response. Ofthese four studies, three show
some concavity in the dose-response curve, but this was
statistically significantonly inthechrysarobin mouse skinstudy
(11). For six of the eight biological parameters, statistically
significantconcavity wasalsodemonstrated inoneormorecase
(only the parameters hepatic foci percent volume [n=6] and
hepatic tumors [n=1] did not show statistically significant
concavity).
Summary
Inthis reviewof22publisheddose-responsestudiesoftumor
promoters, fivescientificfindings areofparticularinterestand
utility. First, bothTPAandchrysarobin show twoandthreeex-
perimental doses, respectively, at which zeropapillomas were
found. Second, the skin dose-response curves have a high
positive slope (a steepcurve; e. g., TPA-induced papillomas in
SENCAR mice: Fig. 9). Third, phenobarbital shows the
strongestevidenceforathresholdofpromotionofcarcinogenesis
in ratliver(Fig. 1). Fourth, theexperimentalevidenceforapro-
tective or antipromotional effect of very low doses of known
hepatic promoters, TCDD and phenobarbital, is fascinating.
Fifth, chloroform, anecrogenic chemical, shows anexperimen-
tal threshold in the dose-response relationship with altered
hepatic foci. This may be the only one of the 11 selected
chemicals that acts primarily through cell death and compen-
satory cell proliferation.
Despite having 22dose-response studies of 11 different pro-
motional chemicals, there aredeficiencies, gaps, problems, and
limitations in the available data. Eight ofthese limitations are
discussedbelow. a) Itisdesirable thatexperimental studies pro-
ceedallthewaytocarcinomaandnotstopatalteredhepatic foci
or mouse skin papillomas. b) It isdesirable to uselonger study
times, up to the full 104 weeks normally employed in car-
cinogenesisbioassays. Withoutlifetime studiesofpromotion, we
cannotknowifalackofresponseisduetoinsufficientdoseofthe
promoterortoinsufficienttimeforthepromotertoact(latency
period). c)Skinpromotionexperimentsshouldincludeaconcur-
rentcontrol groupgivenzerodoseofpromoter. Withoutthis in-
itiated control group one cannot rule out unusual and unan-
ticipatedconfounding influencesonanexperiment.d)Inseveral
cases, particularly with the three HCH isomers, lower dose
groupsare neededtofullydeterminethedose-response curve.
e) Thethresholdofthedose-response relationship forthe pro-
tectiveeffectofTCDDandphenobarbitalonalteredratliverfoci
shouldbedetermined.J) Morenecrogenicchemicals should be
studiedinrespecttotheirpromotional dose-response relation-
ship. Necrogenic chemicals that cause compensatory cell pro-
liferation may be a relatively common class ofchemical pro-
moters. g) Moredataareneeded indifferentanimal species and
organs. We found little dose-response data in experimental
organssuchasfemaleratliver(carcinomastudies), maleratliver
(foci studies), lung, stomach, intestine,breast; andanimals such
asmalemice, hamsters, guineapigs, rabbits, cats, anddogs. h)
To distinguish between various different models ofpromotion
(e.g., linearitywithlogdoseorlinearity witharithmeticdose),
itiscritical thatdosesbeselectedthatwillprovideadequatedata
to subsequently choose between the various possible
mathematical models.
Fordose-response curves ofpromoters ofcarcinogenesis to
be highly useful to biologically based risk assessment models,
these eight limitations should be addressed. Future dose-
response researchonpromoterscanassistinthedevelopmentof
biologically based risk assessment models and contribute to
scientific regulation ofchemicals.
Althoughtheresearchdescribed inthisarticlehasbeensupportedby theU.S.
EPA, thisarticlehas notbeen subjectedtoU.S. EPA review andtherefore does
notnecessarily reflecttheviewsoftheAgency, andnoofficial endorsementshould
be inferred. Mentionoftrade namesorcommercialproductsdoesnotconstitute
endorsement orrecommendation for use.
TheauthorsappreciatemanyhelpfuldiscussionswithJimHolderoftheU.S.
EPA. R. Schulte-Herman kindlyprovided us with the actual rawdata set from
his group's studies with the three isomers ofHCH.
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